CN104193827A - 一种丙型肝炎病毒第一高变区融合抗原及其应用 - Google Patents
一种丙型肝炎病毒第一高变区融合抗原及其应用 Download PDFInfo
- Publication number
- CN104193827A CN104193827A CN201410439852.0A CN201410439852A CN104193827A CN 104193827 A CN104193827 A CN 104193827A CN 201410439852 A CN201410439852 A CN 201410439852A CN 104193827 A CN104193827 A CN 104193827A
- Authority
- CN
- China
- Prior art keywords
- hvr1
- hepatitis
- virus
- antigen
- hcv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 title claims abstract description 107
- 108091007433 antigens Proteins 0.000 title claims abstract description 90
- 239000000427 antigen Substances 0.000 title claims abstract description 86
- 102000036639 antigens Human genes 0.000 title claims abstract description 86
- 230000004927 fusion Effects 0.000 title claims abstract description 55
- 108700006884 Hepatitis C virus HVR1 Proteins 0.000 title abstract description 5
- 241000711549 Hepacivirus C Species 0.000 claims abstract description 86
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 101000666856 Homo sapiens Vasoactive intestinal polypeptide receptor 1 Proteins 0.000 claims 1
- 102100038388 Vasoactive intestinal polypeptide receptor 1 Human genes 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 30
- 230000009260 cross reactivity Effects 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 7
- 208000015181 infectious disease Diseases 0.000 abstract description 6
- 230000003472 neutralizing effect Effects 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 238000004393 prognosis Methods 0.000 abstract description 3
- 102000014150 Interferons Human genes 0.000 abstract description 2
- 108010050904 Interferons Proteins 0.000 abstract description 2
- 229940079322 interferon Drugs 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 238000001976 enzyme digestion Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 3
- 241000711557 Hepacivirus Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 241001227713 Chiron Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 101710118188 DNA-binding protein HU-alpha Proteins 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 101710144128 Non-structural protein 2 Proteins 0.000 description 1
- 101710144111 Non-structural protein 3 Proteins 0.000 description 1
- 101800001020 Non-structural protein 4A Proteins 0.000 description 1
- 101800001019 Non-structural protein 4B Proteins 0.000 description 1
- 101800001014 Non-structural protein 5A Proteins 0.000 description 1
- 101710199667 Nuclear export protein Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940124737 hepatitis-C vaccine Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410439852.0A CN104193827B (zh) | 2014-09-01 | 2014-09-01 | 一种丙型肝炎病毒第一高变区融合抗原及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410439852.0A CN104193827B (zh) | 2014-09-01 | 2014-09-01 | 一种丙型肝炎病毒第一高变区融合抗原及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104193827A true CN104193827A (zh) | 2014-12-10 |
CN104193827B CN104193827B (zh) | 2017-04-12 |
Family
ID=52079220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410439852.0A Active CN104193827B (zh) | 2014-09-01 | 2014-09-01 | 一种丙型肝炎病毒第一高变区融合抗原及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104193827B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104710537A (zh) * | 2015-04-09 | 2015-06-17 | 汪运山 | 柯萨奇病毒ca16 vp1重组抗原及其单克隆抗体与应用 |
CN106432508A (zh) * | 2016-08-30 | 2017-02-22 | 深圳市伯劳特生物制品有限公司 | 一种pla2r‑thsd7a融合蛋白及其应用和试剂盒 |
-
2014
- 2014-09-01 CN CN201410439852.0A patent/CN104193827B/zh active Active
Non-Patent Citations (5)
Title |
---|
D. SCHMIDT MARTIN ET AL: "登录号AER67940", 《GENBANK》 * |
M. ABDEL-FATTAH ET AL: "登录号AEK27049", 《GENBANK》 * |
U. DUMPIS ET AL: "登录号AAM11896", 《GENBANK》 * |
V. ALFONSO ET AL: "登录号AAQ81957", 《GENBANK》 * |
VICTORIA ALFONSO ET AL: "Evolutionary study of HVR1 of E2 in chronic hepatitis C virus infection", 《JOURNAL OF GENERAL VIROLOGY》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104710537A (zh) * | 2015-04-09 | 2015-06-17 | 汪运山 | 柯萨奇病毒ca16 vp1重组抗原及其单克隆抗体与应用 |
CN106432508A (zh) * | 2016-08-30 | 2017-02-22 | 深圳市伯劳特生物制品有限公司 | 一种pla2r‑thsd7a融合蛋白及其应用和试剂盒 |
Also Published As
Publication number | Publication date |
---|---|
CN104193827B (zh) | 2017-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111393532B (zh) | 新型冠状病毒优势表位融合蛋白、诊断试剂及应用 | |
CN108912213B (zh) | 肠道病毒71型vp1抗原的免疫原性多肽及其制备方法与应用 | |
CN104650195B (zh) | Ev71病毒vp1重组抗原及其单克隆抗体与应用 | |
CN105602908B (zh) | 水貂γ-干扰素单克隆抗体及其在检测水貂γ-干扰素中的应用 | |
CN107459562B (zh) | 重组表达的腺病毒纤毛蛋白肽、腺病毒亚单位疫苗及其制备方法 | |
CN110551212A (zh) | 抗gii.4型诺如病毒衣壳蛋白vp1和病毒样颗粒vlp单克隆抗体的制备方法和应用 | |
CN111944044A (zh) | 一种抗ASFV-p30蛋白的纳米抗体及其制备方法和应用 | |
CN103864936B (zh) | Hpv18型l2ne7e6融合蛋白基因、表达载体、方法、菌株和用途 | |
CN110845624B (zh) | 一种sumo-cp融合蛋白及其制备方法以及其多克隆抗体的制备方法 | |
CN104193827B (zh) | 一种丙型肝炎病毒第一高变区融合抗原及其应用 | |
CN111647055A (zh) | 一种用于新型冠状病毒检测的n蛋白及其制备与应用 | |
CN102690336A (zh) | 蝙蝠sars样冠状病毒刺突蛋白免疫决定区及制备方法和用途 | |
US11767356B1 (en) | Canine parvovirus nanobody CPV-VHH-E3 and application thereof | |
CN105254724B (zh) | 截短型丙型肝炎病毒hcv ns3抗原及其制备与应用 | |
Ganguly et al. | Enhanced prokaryotic expression of dengue virus envelope protein | |
ES2374812T3 (es) | Método para detectar o medir vhb. | |
CN113736825B (zh) | 一种表达猪非典型瘟病毒融合蛋白的重组果蝇细胞系及其制备方法和应用 | |
CN113248578B (zh) | 新型冠状病毒(2019-nCoV)重组抗原及多克隆抗体 | |
CN115772230A (zh) | 一种rsv重组抗原、其制备方法及应用 | |
CN113845577A (zh) | SARS-CoV-2特异性多肽及其应用 | |
CN112813080B (zh) | 一种人工密码子优化的猪瘟病毒e2蛋白及其制备方法与用途 | |
Hwang et al. | Identification of humoral antigenic determinants in the hepatitis C virus NS3 protein | |
CN111848815A (zh) | 猪戊型肝炎基因4型病毒和猪口蹄疫o型病毒中和抗原表位嵌合蛋白及其制备方法与应用 | |
Takao et al. | Antibody reactive to a hepatitis C virus (HCV)‐derived peptide capable of inducing HLA‐A2 restricted cytotoxic T lymphocytes is detectable in a majority of HCV‐infected individuals without HLA‐A2 restriction | |
CN112940081B (zh) | 可特异性结合新型冠状病毒核衣壳蛋白的多肽分子及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Xu Wei Inventor after: Zhu Zhiwei Inventor after: Chen Zhen Inventor after: Ding Zhaoming Inventor after: Wang Yan Inventor after: Ou Lanxiang Inventor after: Wang Jiaying Inventor after: Kou Zongyang Inventor after: Ding Xinglong Inventor after: Wang Heng Inventor before: Chen Zhen Inventor before: Ding Zhaoming Inventor before: Wang Yan Inventor before: Ou Lanxiang Inventor before: Wang Jiaying Inventor before: Kou Zongyang Inventor before: Ding Xinglong Inventor before: Wang Heng Inventor before: Zhu Zhiwei |
|
COR | Change of bibliographic data | ||
GR01 | Patent grant | ||
GR01 | Patent grant |